Abstract:
본 발명은 프로브의 길이 차이에 의존하여 카피 수를 분석하는 기존의 MLPA(Multiplex Ligation-dependent Probe Amplification) 기술을 변형한 것으로, 프로브의 길이 차이에 관계없이 프로브의 입체 구조에 따른 이동상의 차이에 따라 카피 수 다형성을 다중 검출하는 방법 및 상기 방법을 구현하기 위한 키트에 관한 것이다.
Abstract:
PURPOSE: A composition containing VPREB1 gene for diagnosing chronic rheumatoid arthritis is provided to measure replication simply and exactly diagnose the disease or possibility of developing the disease. CONSTITUTION: A composition for diagnosing chronic arthritis rheumatoid contains a probe or a primer having a sequence which is complementary to a nucleotide sequence of VPREB1 gene. VPREB1 has a nucleotide of sequence number 1 on chromosome 22q11.2. The primer contains primers of sequence numbers 2 and 3 or 6 and 7. The risk of developing Chronic arthritis rheumatoid is determined when the copy number of VPREB1 gene is under 2. A kit for diagnosing chronic arthritis rheumatoid contains the probe or primer.
Abstract:
A method for predicting autism using copy number variation of genome is provided to predict risk factor of autism generation through copy number variation of genome. A method for predicting autism using a copy number variation (CNV) of genome comprises: a step of observing copy number variation of genome; and a step of confirming the expression variation of CNV. A kit for predicting autism comprises a microarray and optical measurement device. The microarray comprises a gene probe for CNV observation related to autism. The optical measurement device measures the expression variation of specific gene on CNV.
Abstract:
A diagnosis method of cancer prognosis using comparative genomic hybridization is provided to early diagnose determine prognosis by measuring the expression variation and selecting cancer relating gene. A method for determining diagnosis and prognosis hepatocellular carcinoma (HCC) comprises: a step of observing genomic variation area (RAR) on chromosome; and a step of obtaining the RAR-G1~RAR-G14 and measuring RAR expression variation among RAR groups related to hepatocellular carcinoma of RAR-G1~RAR-L18. The RAR groups related to hepatocellular carcinoma is RAR-G1, RAR-G2, RAR-L17, RAR-G9, RAR-L5 or RAR-L8. The RAR-G9, RAR-G12, RAR-G13 and RAR-L3 are used in determining of the microvasculature transition prognosis. A kit for determining diagnosis or prognosis of hepatocellular carcinoma comprises: a micro array containing a RAR observation gene probe for observing RAR-G1~RAR-G14 and RAR-L1~RAR-L18; and an optical device for measuring expression variation of specific gene on RAR phase.
Abstract:
본 발명은 DNA 반복염기서열(repeat sequence)을 선택 농축한 DNA 라이브러리 및 이의 제조방법에 관한 것으로, 간략하게 포유동물의 조직으로부터 게놈(genomic) DNA를 분리하는 단계와 초음파 파쇄(sonication)를 일정한 크기로 DNA를 절단하는 단계, 및 가열 변성후 재교잡하여 교잡화되지 않은 단일사슬부분을 단일사슬 선택적 뉴클리아제를 이용하여 제거함으로서 반복서열을 선택 농축한 DNA 라이브러리 및 이의 제조방법에 관한 것이다. 반복염기서열, DNA 라이브러리
Abstract:
The present invention relates to a composition for a systemic lupus erythematosus risk prediction. In detail, in case where copy number variants of 1q25.1, C4 and 10q21.3 loci occur, the variants are regarded as high-risk groups for a systemic lupus erythematosus through the composition. The composition of the present invention enables prediction for the risk of systemic lupus erythematosus as the copy number variants of the three loci have a synergy effect for a development of systemic lupus erythematosus. Furthermore, the present invention is a test-friendly method which reduces analytical errors which may be created due to a new equipment purchased or technological limitations as a PCR generally implemented in a inspection room of majority of hospitals is used. In addition, the present invention is able to apply a non-invasive method to a person to be tested. Ultimately, the present invention predicts the risk of systemic lupus erythematosus which will essentially contribute to delaying development of the disease or to preventing an aggravation of state.
Abstract:
본 발명은 전체 게놈중 유전자 변이를 스크리닝하는 방법을 사용하여 폐암 및 폐암의 하부 유형을 진단하는 방법에 대한 것이다. 구체적으로는 게놈-와이드 어레이 CGH를 폐암 조직으로부터 추출된 DNA에 적용하여, 폐암 및 폐암의 하부유형에 특이한 유전 변이들을 확인하여 이를 폐암 및 폐암의 하부유형에 대한 정확한 진단을 하는데 제공하는 것을 목적으로 한다. 또한 본 발명은 폐암에 특이한 유전변이를 폐암 진행에 있어서의 예후적 표지자로 사용하는 방법에 관한 것이다. 폐암, 유전변이
Abstract:
본발명은 DNA 복제수변이(DNA copy number variants)를이용하는강직성척추염발병위험도예측방법에관한것이다. 본발명의 DNA 복제수변이검출용프라이머를이용하여, 강직성척추염발병위험도를효과적으로예측할수 있으며, 단일염기다형성(SNP) 측정결과를접목시킴으로써상기예측의민감도와특이도를증진시킬수 있음을확인하였는바, 강직성척추염의예방및 치료에있어서보다근본적으로접근할수 있을것으로기대된다.